Tools for Practice Outils pour la pratique


#97 Fibrates: Statin’s Trusty Sidekick or Lackluster Fallback?


CLINICAL QUESTION
QUESTION CLINIQUE
Do fibrates reduce cardiovascular (CV) events?


BOTTOM LINE
RÉSULTAT FINAL
When used alone, fibrates reduce non-fatal coronary events, but have no effect on mortality or other CV events, including stroke. Current evidence suggests fibrates provide no advantage when added to statin therapy.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
At least ten systematic reviews evaluate fibrates oCV disease with similar findings.1-10 Focusing on the most up-to-date and complete: 
  • Meta-analysis1 of 18 trials (45,058 patients) of fibrates versus placebo over one to six years: 
    • 10% (confidence interval 0-18%) relative risk reduction (RRR) in CV events.  
      • Primarily due to a 19% RRR in non-fatal coronary events. 
    • No significant effect on all-cause mortality, vascular mortality or stroke. 
    • Coronary benefits seen in both primary and secondary prevention trials. 
  • Only one trial (ACCORD11) evaluated fibrate or placebo added to statin therapy: 
    • No statistically significant difference in cardiovascular events over 4.7 years. 
      • Fenofibrate 10.5%, placebo 11.3% (p=0.32). 
Context:  
  • The latest Canadian dyslipidemia guidelines12 recommend against routine use of fibrates in patients taking statins. 
  • Before initiating a fibrate, consider optimizing other CV interventions that provide a better value, for example: 
    • In a primary prevention patient with 10% risk of CV disease over 10 years: 
      • Fibrates reduce CV risk to 9%;1 
      • Statins reduce CV risk to 7.5%;13 
      • Thiazides reduce CV risk to 7%.14 
    • Whereas fibrate benefits are limited to non-fatal coronary events, statins and thiazides also reduce stroke and mortality risk. 
  • Theoretically fibrates could reduce the risk of pancreatitis (by reducing triglycerides). The best evidence15 suggests they do the opposite: 
    • Fibrates increase pancreatitis (Number Needed to Harm (NNH)=935) at five years. 
    • Statins reduce pancreatitis (Number Needed to Treat (NNT)=1200) at five years. 
  • Additional potential adverse effects associated with fibrates include: 
    • Venous thromboembolism (NNH ~110)16 over five years; 
    • Acute kidney injury (NNH ~450)17 during first three months of initiation; 
    • Rhabdomyolysis over five years for fibrates (NNH ~5050) and for fibrates with statins (NNH ~1975).18  
updated jan 27 2018 by ricky


Latest Tools for Practice
Derniers outils pour la pratique

#359 Topical corticosteroids for atopic dermatitis - More than skin deep

What are the benefits/harms of topical corticosteroids for atopic dermatitis in adults/children?
Read Lire 0.25 credits available Crédits disponibles

#358: Any berry good solutions to preventing UTIs: Cranberries?

Do cranberry products prevent recurrent urinary tract infections (UTIs)?
Read Lire 0.25 credits available Crédits disponibles

#357: Overcoming Resistance: Antipsychotics for difficult to treat depression

In patients with treatment-resistant depression, is adding an atypical antipsychotic to current therapy safe and effective?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • G. Michael Allan MD CCFP
  • Ricky D. Turgeon BSc(Pharm) ACPR PharmD

1. Jun M, Foote C, Lv J, et al. Lancet. 2010; 375:1875-84.

2. Abourbih S, Filion KB, Joseph L, et al. Am J Med. 2009; 122:962.e1-962.e8.

3. Saha SA, Kizhakepunnur LG, Bahekar A, et al. Am Heart J. 2007; 154:943-53.

4. Robins SJ, Bloomfield HE. Curr Opin Lipidol. 2006 Aug; 17(4):431-9.

5. Loomba RS, Arora R. Am J Ther. 2010 Nov-Dec; 17(6):e182-8.

6. Saha SA, Arora RR. Int J Cardiol. 2010 May 28; 141(2):157-66.

7. Birjmohun RS, Hutten BA, Kastelein JJ, et al. J Am Coll Cardiol 2005; 45:185-97.

8. Studer M, Briel M, Leimenstoll B, et al. Arch Intern Med. 2005; 165:725-730.

9. Wang D, Liu B, Tao W, Hao Z, Liu M. Cochrane Database Syst Rev 2015;10:CD009580.

10. Jakob T, Nordmann AJ, Schandelmaier S, Ferreira-Gonzalez I, Briel M. Cochrane Database Syst Rev 2016;11:CD009753.

11. The ACCORD Study Group. N Engl J Med. 2010; 362:1563-74.

12. Anderson TJ, Gregoire J, Pearson GJ, et al. Can J Cardiol 2016;32:1263-82.

13. Taylor F, Huffman MD, Macedo AF, et al. Cochrane Database Syst Rev. 2013; (3):CD004816.

14. Wright HM, Musini VM. Cochrane Database Syst Rev. 2009; (3):CD001841.

15. Preiss D, Tikkanen MJ, Welsh P, et al. JAMA. 2012; 308:804-11.

16. Squizzato A, Galli M, Romualdi E, et al. Eur Heart J. 2010; 31:1248-56.

17. Zhao YY, Weir MA, Manno M, et al. Ann Intern Med. 2012; 156:560-9.

18. Amend KL, Landon J, Thyagarajan V, et al. Ann Pharmacother. 2011; 45:1230-9.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.